# Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

> **NCT05733715** · EARLY_PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab infusion
- **DRUG:** Lenvatinib tablet

## Key facts

- **NCT ID:** NCT05733715
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-03
- **Primary completion:** 2026-06
- **Final completion:** 2028-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733715, "Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05733715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*